Slide 1: Half-Year Financial Report 1–6/2017
Orion Half-Year Financial Report 1–6/2017
Slide 2: Disclaimer
Disclaimer This presentation contains forward-looking statements which involve risks and uncertainty factors. These statements are not based on historical facts but relate to the Company’s future activities and performance. They include statements about future strategies and anticipated benefits of
Slide 3: Year has progressed as planned
Year has progressed as planned H1 2016 H1 2017 ● Net sales grew slightly from the comparative 535 552 period. ● Operating profit at similar level to previous year. ● Easyhaler product family maintained good growth. Dexdor, biosimilar Remsima, Fermion and Animal 164 164 Health also increased sales. ●
Slide 4: Geographical breakdown of net sales
Geographical breakdown of net sales H1 2017 Orion’s sales network Finland 17% Scandinavia 30% 6% Other Europe North America 30% 17% ROW 4 19 July 2017 Half-Year Financial Report 1–6/2017 © Orion Corporation
Slide 5: Breakdown of net sales by business division
Breakdown of net sales by business division Net sales, H1 H1 EUR million 2017 2016 Change Proprietary Products Specialty Products 255 246 +4% 3% 5% Specialty Products Proprietary Products 186 185 +0% 5% 34% 7% Animal Health Animal Health 41 38 +7% Fermion Fermion 28 20 +39% Contract Contract manufac
Slide 6: Pharmaceuticals business
Pharmaceuticals business 6 19 July 2017 Half-Year Financial Report 1–6/2017 © Orion Corporation
Slide 7: Best-selling pharmaceuticals H1 2017
Best-selling pharmaceuticals H1 2017 Net sales, Change vs. Product Indication EUR million H1 2016 1. Parkinson’s disease 58 -19% 2. Asthma, COPD 37 +16% 3. Intensive care sedative 34 +22% 4. Acute decompensated heart failure 30 +8% Rheumatoid arthritis, inflammatory 5. bowel diseases 28 +28% 6. Anim
Slide 8: Proprietary Products
Proprietary Products Breakdown of net sales ● As expected, sales of Stalevo, Comtess and Comtan continued to decline, but good Stalevo, Comtess growth of other products compensated for & Comtan the decrease. Easyhaler 8% ● Easyhaler product family, Dexdor and Simdax 7% sales increased. 31% Dexdor ●
Slide 9: Parkinson's drugs
Parkinson’s drugs Sales, EUR million Sales of Orion’s 60 branded Parkinson’s drugs 50 by market area MAT3/2017* 3% 40 30 20 27% Europe 41% 10 Japan 0 ROW Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 USA 2013 2014 2015 2016 2017 29% Orion sales Deliveries to Novartis *Source: IMS Health sales s
Slide 10: Easyhaler product family
Easyhaler product family Sales, EUR million 20 ● Total Easyhaler product family sales grew by 16%. 18 16 ● Bufomix Easyhaler sales grew by 31%. 14 12 ● Marketing authorisation application for Easyhaler 10 salmeterol-fluticasone combined formulation 8 submitted in Europe. 6 ● Easyhaler budesonide-for
Slide 11: Dexdor intensive care sedative
Dexdor intensive care sedative Sales, EUR million European sedative market 18 MAT3/2017* 16 Total market value Propofol EUR 346 14 EUR 530 million (+1%) million (-0%) 12 10 Midazolam EUR 67 8 13% million (-9%) 6 4 10% Dexmedetomidine 2 65% EUR 53 million 0 12% (+39%) Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4
Slide 12: Specialty Products
Specialty Products Net sales in key markets H1 2017 Breakdown of net sales vs. H1 EUR million 2016 Finland Finland 145 +2% 13% Scandinavia 47 +12% Scandinavia Eastern Europe and Russia 30 +15% 12% • Sales of self-care products and biosimilar Remsima developed well. Growth in net sales of Remsima was
Slide 13: Orion strong in home market Finland
Orion strong in home market Finland Finnish human pharmaceuticals market H1 2017: Finland’s biggest pharmaceutical companies H1 2017, EUR million 200 ● Wholesale EUR 1,131 million 147 ● Orion's market share 13% 150 ● Growth of total market +1% 100 ● Orion's growth +2% 61 67 50 52 53 – Orion's growth
Slide 14: Key clinical pharmaceutical development projects
Key clinical pharmaceutical development projects Project Indication PHASE Registration Bioequivalence Easyhaler® salmeterol-fluticasone Asthma, COPD Registration study Darolutamide (ODM-201) 1) Prostate cancer (nmCRPC) I II III Darolutamide (ODM-201) 1) Prostate cancer (mHSPC) I II III ODM-109 (oral
Slide 15: Diagnostics business
Diagnostics business 15 19 July 2017 Half-Year Financial Report 1–6/2017 © Orion Corporation
Slide 16: Orion Diagnostica
Orion Diagnostica H1 2016 H1 2017 28 27 ● QuikRead® tests remained the main product. ● Net sales decreased due to, among other things, periodisation of purchases by significant collaboration partner. 4.4 4.8 Net sales, Operating profit, EUR million EUR million -4% +8% 16 19 July 2017 Half-Year Finan
Slide 17: Outlook for 2017
Outlook for 2017 (provided on 8 February 2017) Net sales are estimated to be at similar level to 2016 Net sales (net sales were EUR 1,074 million in 2016). Operating profit excluding material capital gains is estimated to be at least EUR Operating profit 280 million (operating profit excluding capit
Slide 18: Orion Calendar 2017–2018
Orion Calendar 2017–2018 Interim Report January–September 2017 Thursday 26 October 2017 Financial Statement Release for 2017 Wednesday 7 February 2018 Planned to be held on Annual General Meeting 2018 Tuesday 20 March 2018 Interim Report January–March 2018 Tuesday 24 April 2018 Half-Year Financial R
Slide 19: Building well-being. Together.
Building well-being. Together.